Spago Nanomedical announce that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application comprising product protection for Tumorad in the USA.
Tumorad is based on nanoparticles loaded with a radioisotope and holds potential to become a new treatment of solid tumors. Earlier this year the USPTO issued a preliminary approval by means of a Notice of Allowance. The USPTO has now informed Spago Nanomedical that the patent was approved on June 19.
The patent, with the title “Nanostructures and applications thereof”, has been assigned patent number US 9,999,963 and is valid until year 2035.
The approval means that Spago Nanomedical holds product protection for Tumorad in one of the strategically most important markets for radionuclide therapies. Further approvals in other territories, e.g. EU and Japan, are pending.
Image showing Tumorad
